Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04881240 · ClinicalTrials.gov registry record · Phase 1
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
A Phase 1 study of Pediatric ALL and Acute Lymphoblastic Leukemia, in Relapse, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04881240 is a Phase 1 study of Pediatric ALL and Acute Lymphoblastic Leukemia, in Relapse that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 60 participants, below the 1,645-participant average among 21 other Pediatric ALL trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04881240, a Phase 1 study of Pediatric ALL and Acute Lymphoblastic Leukemia, in Relapse, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old with relapsed and/ or refractory CD19-positive leukemia. Primary Objective To determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with allogeneic CD19-CAR.CD45RA-negative T-cells in pediatric, adolescent and young adult patients ≤ 21 years of age, with relapsed and/or refractory CD19-positive leukemia. Secondary Objectives * To evaluate the anti-leukemic activity of allogeneic CD19-CAR.CD45RA-negative T-cells. * To determine rates and severity of graft-versus-host-disease (GVHD) after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells. Exploratory Objectives * To study the expansion, persistence and phenotype of allogeneic CD19-CAR.CD45RA-negative T-cells. * To characterize the cytokine profile in the peripheral blood and CSF after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells. * To assess whether allogeneic CD19-CAR.CD45RA-negative T-cells acquire functional versus exhaustion-associated epigenetic programs. * To determine immune reconstitution post treatment, and the clonal structure and endogenous repertoire of allogeneic CD19-CAR.CD45RA-negative T-cells and relate inferred specificity to CAR response profiles. * To characterize incidence and mechanisms of relapse post-therapy with allogeneic CD19-CAR.CD45RA-negative T-cells.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mesna
- DEVICE CliniMACS
- BIOLOGICAL CD19-CAR(Mem) T-cells
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-02-14 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04881240
The ClinicalTrials.gov registry entry for NCT04881240 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,645-participant average among 21 other Pediatric ALL trials with a reported enrollment target (96% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pediatric ALL appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04881240 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT04881240 about?
NCT04881240 is a clinical study titled "Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia". This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old with relapsed and/ or re...
What is the current status of trial NCT04881240?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-02-14. Estimated completion is 2028-07-01.
What conditions does trial NCT04881240 study?
This clinical trial studies the following conditions: Pediatric ALL, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory.
What interventions are being tested in trial NCT04881240?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mesna (DRUG), CliniMACS (DEVICE), CD19-CAR(Mem) T-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04881240?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04881240 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric ALL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)
RECRUITING · NA
-
PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS
RECRUITING · NA
-
Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy
RECRUITING · NA
-
Feasibility/Acceptability of Attentional-Control Training in Survivors
RECRUITING · NA
-
Pharmacokinetics of Drugs Administered to Children
RECRUITING
-
HEalth Advocate for Liver Transplant - Pilot
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.